Part 1: Up to 70% of people with MS suffer from cognitive dysfunction, which can have a profound impact on everyday life. Treatment can include cognitive rehabilitation, exercise and medication. This symposium will provide an evidence-based perspective on treatment approaches for cognitive dysfunction and discuss how these treatments can be incorporated into clinical practice. The symposium will be geared to providing clinicians with practical information and guidance in the understanding, impact, and treatment of cognitive dysfunction in MS. The challenges of implementing treatment for cognitive dysfunction as part of usual clinical care for MS patients will be the major focus of this symposium. Level of Information: Intermediate Part 2: Cognitive issues are a prominent problem for people with multiple sclerosis (pwMS). In fact, up to half of all pwMS will suffer from some form of cognitive impairment during their disease course, with a strong impact on quality of life and employment. However, recognizing that cognition is an issue in MS has been difficult, due to the somewhat hidden nature of these disabilities in daily practice and a lack of clear diagnostic criteria. The International MS Cognition Society (IMSCOGS) in collaboration with ECTRIMS and CMSC has developed the Delphi consensus diagnostic criteria and recommendations regarding the diagnosis and monitoring of cognitive impairment in MS, which will be published in early 2026. In this session we will discuss how these criteria were developed and how they should be applied in both clinical and research applications to diagnose and monitor cognitive impairment in MS. Subsequently, we will discuss how the criteria can be supported with MRI and how they fit in the 2024 McDonald diagnostic criteria for diagnosing MS and recent insights into progression, such as progression independent of relapse activity (PIRA). Level of Information: Intermediate, AdvancedPart 1: Up to 70% of people with MS suffer from cognitive dysfunction, which can have a profound impact on everyday life. Treatment can include cognitive rehabilitation, exercise and medication. This symposium will provide an evidence-based perspective on treatment approaches for cognitive dysfunction and discuss how these treatments can be incorporated into clinical practice. The symposium will be geared to providing clinicians with practical information and guidance in the understanding, impact, and treatment of cognitive dysfunction in MS. The challenges of implementing treatment for cognitive dysfunction as part of usual clinical care for MS patients will be the major focus of this symposium. Level of Information: Intermediate Part 2: Cognitive issues are a prominent problem for people with multiple sclerosis (pwMS). In fact, up to half of all pwMS will suffer from some form of cognitive impairment during their disease course, with a strong impact on quality of life and employment. However, recognizing that cognition is an issue in MS has been difficult, due to the somewhat hidden nature of these disabilities in daily practice and a lack of clear diagnostic criteria. The International MS Cognition Society (IMSCOGS) in collaboration with ECTRIMS and CMSC has developed the Delphi consensus diagnostic criteria and recommendations regarding the diagnosis and monitoring of cognitive impairment in MS, which will be published in early 2026. In this session we will discuss how these criteria were developed and how they should be applied in both clinical and research applications to diagnose and monitor cognitive impairment in MS. Subsequently, we will discuss how the criteria can be supported with MRI and how they fit in the 2024 McDonald diagnostic criteria for diagnosing MS and recent insights into progression, such as progression independent of relapse activity (PIRA). Level of Information: Intermediate, Advanced
